- Home
- SITC vs HURA Comparison
SITC vs HURA Comparison
Compare SITC & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SITC | HURA |
|---|---|---|
| Founded | 1965 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 154.8M | 160.5M |
| IPO Year | 1994 | 2010 |
Fundamental Metrics
Financial Performance| Metric | SITC | HURA |
|---|---|---|
| Price | $3.50 | $1.98 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.04 |
| AVG Volume (30 Days) | ★ 728.7K | 181.3K |
| Earning Date | 11-04-2026 | 11-13-2026 |
| Dividend Yield | ★ 89.02% | N/A |
| EPS Growth | N/A | ★ 47.93 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $123,649,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.80 | $0.41 |
| 52 Week High | $8.97 | $3.43 |
Technical Indicators
Market Signals| Indicator | SITC | HURA |
|---|---|---|
| Relative Strength Index (RSI) | 67.41 | 49.24 |
| Support Level | $2.89 | $2.04 |
| Resistance Level | $4.55 | $2.23 |
| Average True Range (ATR) | 0.09 | 0.09 |
| MACD | 0.07 | 0.01 |
| Stochastic Oscillator | 97.32 | 48.33 |
Price Performance
Historical ComparisonAbout SITC SITE Centers Corp.
SITE Centers Corp is a self-administered and self-managed REIT that operates as a fully integrated real estate company. The company is engaged in the business of owning, leasing, acquiring, redeveloping, developing, and managing shopping centers.
About HURA TuHURA Biosciences Inc.
TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company operates in one reportable segment, which includes all activities related to advancing therapies for cancer treatment.